A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer

References

• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Compérat E, Cowan NC, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Malmström P-U, Gårdmark T, Sherif A, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016. Scand J Urol. 2019;53(4):193–199.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238.
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297–303.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and Meta-analysis of individual patient data advanced bladder cancer (ABC) Meta-analysis collaboration. Eur Urol. 2005;48(2):202–205. Augdiscussion 205-6.
   PubMed Web of Science ®Google Scholar
• Jerlström T, Chen R, Liedberg F, et al. No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World J Urol. 2020;38(2):381–388.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Frank I, Mason RJ, et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur Urol. 2017;72(5):660–664.
   PubMed Web of Science ®Google Scholar
• Lavery HJ, Stensland KD, Niegisch G, et al. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. J Urol. 2014;191(4):898–906.
   PubMed Web of Science ®Google Scholar
• Martini A, Jia R, Ferket BS, et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. 2019;125(18):3155–3163.
   PubMed Web of Science ®Google Scholar
• Salminen A, Montoya Perez I, Klén R, et al. Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer. BLC. 2019;5(4):273–279.
   Web of Science ®Google Scholar
• Seiler R, Al Deen Ashab H, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–554.
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol. 2019;75(2):231–239.
   PubMed Web of Science ®Google Scholar
• Font A, Domènech M, Benítez R, et al. Immunohistochemistry-Based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy. Cancers (Basel). 2020;12(7):1784.
   Web of Science ®Google Scholar
• Vollmer T, Schlickeiser S, Amini L, et al. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Sci Transl Med. 2021;13(576):eabb3735.
   PubMed Web of Science ®Google Scholar
• Türker P, Wernroth M-L, Malmström P-U, et al. Combination of biomarkers for neoadjuvant systemic chemotherapy before cystectomy in patients with urinary bladder cancer. Transl Res. 2021;235:77–84.
   PubMed Web of Science ®Google Scholar
• During VA, Sole GM, Jha AK, et al. Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours. Ann R Coll Surg Engl. 2016;98(8):547–551.
   PubMed Web of Science ®Google Scholar
• Mariappan P, Lavin V, Phua CQ, et al. Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study. Urology. 2017;109:134–139.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Soloway MS, Eldefrawy A, et al. Prognostic significance of cystoscopy findings following neoadjuvant chemotherapy for muscle-invasive bladder cancer. Can J Urol. 2015;22(2):7690–7697.
   PubMed Web of Science ®Google Scholar
• Becker REN, Meyer AR, Aaron Brant A, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2021;79(3):364–371.
   PubMed Web of Science ®Google Scholar
• Alvaeus J, Rosenblatt R, Johansson M, et al. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. World J Urol. 2020;38(9):2207–2213.
   PubMed Web of Science ®Google Scholar
• Zirakzadeh AA, Kinn J, Krantz D, et al. Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. Clin Immunol. 2017;176:63–70.
   PubMed Web of Science ®Google Scholar
• Winerdal ME, Krantz D, Hartana CA, et al. Urinary bladder cancer tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol Res. 2018;6(5):528–538.
   PubMed Web of Science ®Google Scholar
• Hartana CA, Ahlén Bergman E, Zirakzadeh AA, et al. Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway. PLoS One. 2018;13(7):e0200079.
   PubMed Web of Science ®Google Scholar
• Hartana CA, Ahlén Bergman E, Broomé A, et al. Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol. 2018;194(1):39–53.
   PubMed Web of Science ®Google Scholar
• Ahlén Bergman E, Hartana CA, Johansson M, et al. Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. Clin Epigenetics. 2018;10(1):102.
   PubMed Web of Science ®Google Scholar
• Krantz D, Hartana CA, Winerdal ME, et al. Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder Cancer. Eur Urol. 2018;74(6):688–692.
   PubMed Web of Science ®Google Scholar